{
    "patient": {
        "Name": "Amanda Payne",
        "DateOfBirth": "1972-11-07",
        "Sex": "Male",
        "Diagnosis": "Invasive lobular carcinoma",
        "BodyPart": "Breast",
        "Physician": "Dr. Donald Fowler",
        "TreatingInstitution": "Lopez, Fisher and Bryan"
    },
    "specimen": {
        "Tumor specimen": {
            "source": "Breast",
            "CollectedDate": "2023-09-16",
            "ReceivedDate": "2023-09-18",
            "TumorPercentage": "59%"
        },
        "Normal specimen": {
            "source": "Blood",
            "CollectedDate": "2023-09-23",
            "ReceivedDate": "2023-09-29"
        }
    },
    "genomic variants": {
        "Somatic - Potentially Actionable": [
            {
                "Gene": "FOXL2",
                "DNA Alteration": "c.402C>G",
                "GeneMutation": "p.C134W Nonsense-GOF",
                "VariantAlleleFraction": "15.4%"
            }
        ],
        "Somatic - Biologically Relevant": [
            {
                "Gene": "NF1",
                "DNA Alteration": "c.6926del",
                "GeneMutation": "p.C134W Spliceregionvariant-GOF",
                "VariantAlleleFraction": "33.58%"
            },
            {
                "Gene": "CDKN2A",
                "DNA Alteration": "c.151G>A",
                "GeneMutation": "p.N1465S Frameshift-GOF",
                "VariantAlleleFraction": "24.97%"
            }
        ],
        "Germline - Pathogenic": [],
        "Pertinent Negatives": [
            "BLM",
            "RB1",
            "BRCA2",
            "CSF3R"
        ]
    },
    "immunotherapy markers": [
        {
            "marker_name": "Tumor Mutational Burden",
            "TmbValue": "1 m/Mb",
            "Tmbpercentile": "58%",
            "Status type": "Microsatellite Instability Status",
            "statusvalue": "High"
        }
    ],
    "FDA-Approved Therapies": {
        "Current Diagnosis": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ],
        "Other Indications": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ]
    },
    "Additional Indicators": [
        {
            "description": "Unfavorable Prognosis",
            "therapy": "NCCN, Consensus, Non-Small Cell Lung Cancer",
            "mutation": "KRASp.G12C Gain-of-function"
        }
    ],
    "Clinical trials": [
        {
            "description": "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer ",
            "phase": "Phase 2",
            "mutations": [
                "KRAS"
            ]
        },
        {
            "description": "A Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
            "phase": "Phase 1/2",
            "mutations": [
                "KRAS",
                "STK11"
            ]
        },
        {
            "description": "First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. (NCT04471415)",
            "phase": "Phase 1/2",
            "mutations": [
                "NFE2L2",
                "STK11"
            ]
        }
    ],
    "variants of unknown significance": {
        "Somatic": [
            {
                "Gene": "STAG2",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.R1012X Nonsense-LOF",
                "VariantAlleleFraction": "14.49%"
            },
            {
                "Gene": "STAT5B",
                "DNA Alteration": "c.1924A>C",
                "GeneMutation": "p.N713_A714insKGKGGG Spliceregionvariant-GOF",
                "VariantAlleleFraction": "5.58%"
            },
            {
                "Gene": "PRKCA",
                "DNA Alteration": "c.1387G>C",
                "GeneMutation": "p.D463H Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "2.01%"
            },
            {
                "Gene": "BRCA2",
                "DNA Alteration": "c.5946delT",
                "GeneMutation": "p.S1982Rfs*22 Nonsense-GOF",
                "VariantAlleleFraction": "4.43%"
            },
            {
                "Gene": "DICER1",
                "DNA Alteration": "c.5439G>C",
                "GeneMutation": "p.W1831* Nonsense-GOF",
                "VariantAlleleFraction": "1.08%"
            },
            {
                "Gene": "CSF1R",
                "DNA Alteration": "c.1085A>G",
                "GeneMutation": "p.N648S Spliceregionvariant-LOF",
                "VariantAlleleFraction": "4.41%"
            },
            {
                "Gene": "CTNNB1",
                "DNA Alteration": "c.98C>T",
                "GeneMutation": "p.D32N Frameshift-LOF",
                "VariantAlleleFraction": "2.63%"
            },
            {
                "Gene": "CHD6",
                "DNA Alteration": "c.4800C>G",
                "GeneMutation": "p.I1600M Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "4.36%"
            },
            {
                "Gene": "MYOD1",
                "DNA Alteration": "c.365T>G",
                "GeneMutation": "p.L122R Nonsense-GOF",
                "VariantAlleleFraction": "5.95%"
            }
        ],
        "Germline": []
    },
    "low coverage regions": [
        "STAT5B",
        "ARID2",
        "MYOD1"
    ],
    "genomic variants details": {
        "Somatic Variant Details - Potentially Actionable": [
            {
                "Gene": "FOXL2",
                "DNA Alteration": "c.402C>G",
                "GeneMutation": "p.C134W Nonsense-GOF",
                "description": "TP53 encodes a protein that is a transcription factor that regulates the expression of genes involved in cell cycle arrest, apoptosis, and DNA repair. TP53 is a tumor suppressor gene that is mutated in many cancers. Mutations in TP53 are associated with cancer progression.",
                "VariantAlleleFraction": "15.4%"
            }
        ],
        "Somatic Variant Details - Biologically Relevant": [
            {
                "Gene": "NF1",
                "DNA Alteration": "c.6926del",
                "GeneMutation": "p.C134W Spliceregionvariant-GOF",
                "description": "FAT1 encodes a transmembrane protein involved in tumor suppressor signaling. FAT1 protein can regulate transcriptional activity by sequestering beta-catenin, thereby preventing it from entering the nucleus. Loss of function mutations and copy number loss of FAT1 are associated with cancer progression.",
                "VariantAlleleFraction": "33.58%"
            },
            {
                "Gene": "CDKN2A",
                "DNA Alteration": "c.151G>A",
                "GeneMutation": "p.N1465S Frameshift-GOF",
                "description": "KRAS is a GDP/GTP binding protein that acts as an intracellular signal transducer. KRAS is involved in several pathways involved in cellular proliferation and survival, including the PI3K-AKT-mTOR pathway and the Ras-Raf-MEK-ERK pathway. Activating mutations, copy number gains, and overexpression of KRAS are associated with cancer progression.",
                "VariantAlleleFraction": "24.97%"
            }
        ]
    },
    "clinical history": {
        "Date": "2023-09-09"
    },
    "other": {
        "ReportId": "1109",
        "ReportDate": "2023-09-25",
        "SignedBy": "Donald Fowler",
        "Supervisor": "Dr. Donna Calderon"
    }
}